Buy, buy buy. CTIX is a winner. Drugs have progressed at excellent levels of speed from laboratory testing to clinical trials. CTIX is not losing money and is in fact performing most tasks for less than the estimates in every 10Q and less than the median costs of most trials. CTIX is frugal. In 3 years the company has gone from one clinical trial to 4 and more to come in the near term. I challenge anyone to find factual proof that this is not a significant accomplishment for so small a company with so little spending, especially considering the current low share price, which is one of the main sources of funding.